Entrada Therapeutics, Inc.
TRDA Healthcare Biotechnology
Entrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024. In the quarter to June 2026, revenue fell 54.0%, EPS grew 2.88% and free cash flow fell 9.10%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TRDA
Entrada Therapeutics, Inc. (TRDA) EV/Sales
As of 16 October 2026, Entrada Therapeutics, Inc. (TRDA) trades at a EV/Sales of −8.3×. Over the past ten years it has ranged from −8.3× (October 2026) to 72.5× (May 2026) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.1× | 375.11% |
| FY2024 | 1.1× | (7.81%) |
| FY2023 | 1.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 18.7× | (60.66%) |
| Mar 2026 | 47.6× | 838.38% |
| Dec 2025 | 5.1× | — |
| Sep 2025 | −1.4× | — |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. compare | −35.1× |
| TRDA Entrada Therapeutics, Inc. | −8.3× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −4.0× |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | 0.5× |
| ADCT ADC Therapeutics SA compare | 1.5× |
| ACOG Alpha Cognition Inc. compare | 9.0× |
| YARW Yarrow Bioscience, Inc compare | 124× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)